DME

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared to nonpregnant controls.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

4D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for potential market approval.

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

4D-150 is an investigational agent designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

Yasha S. Modi, MD, discusses promising results from the VERONA study on EYP-1901, a potential treatment for diabetic macular edema.

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and aflibercept-yszy 0.05 mL injection (OPUVIZ), referencing EYLEA (aflibercept).

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.

Boehringer Ingelheim initiates the THULITE study, exploring an oral treatment for diabetic macular edema.

Yesafili is the first biosimilar to Eylea to be approved by Health Canada.

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision and combat global blindness.

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better support patient care.

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.

Lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients

The ELEVATUM study explored faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities, showcasing significant visual acuity improvements.

Matthew Starr, MD, highlights the RHONE-X trial's findings on faricimab, showcasing improved vision and reduced treatment burden for diabetic macular edema patients.

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer disease and diabetic macular edema (DME).